Related Experiment Video

Updated: Jun 19, 2026

Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation
11:24

Measuring DNA Damage and Repair in Mouse Splenocytes After Chronic In Vivo Exposure to Very Low Doses of Beta- and Gamma-Radiation

Published on: July 3, 2015

11.5K

The Outcome and Impact of Academic Cancer Clinical Trials with Participation from Canadian Sites (2015-2024)

Rebecca Y Xu1, Diana Kato1, Victoria Percival2

  • 1Canadian Cancer Clinical Trials Network, Toronto, ON M5G 0A3, Canada.

Cancers
|December 30, 2025
PubMed
Abstract

Insights

Academically sponsored cancer clinical trials supported by the Canadian Cancer Clinical Trials Network (3CTN) show high completion and reporting rates. Modest public investment significantly impacts cancer care and policy.

Area of Science:

  • Oncology
  • Clinical Research
  • Health Services Research

Background:

  • Academically sponsored cancer clinical trials (ACCTs) are crucial for patient-centered care, especially in underserved areas.
  • The Canadian Cancer Clinical Trials Network (3CTN) provides infrastructure and funding for multi-center ACCTs.
  • Annual funding averaged CAD 4.3 million from federal and provincial sources between 2015 and 2024.

Purpose of the Study:

  • To evaluate the outcomes and impact of ACCTs supported by 3CTN from 2015 to 2024.
  • To assess trial characteristics, results, publication rates, and guideline incorporation.
  • To demonstrate the value of sustained infrastructure and public investment in cancer research.

Main Methods:

  • Descriptive analysis of 350 closed ACCTs with primary completion dates within the study period.
  • Data sources included registry data, peer-reviewed publications, and oncology guideline searches.
  • Assessment of trial characteristics, publication rates, and guideline incorporation.

Main Results:

  • 36% of Phase III trials were incorporated into clinical practice guidelines, with an additional 7% likely to be incorporated.
  • 81% of trials were published in journals, and 45% posted results in public registries.
  • Trials covered diverse cancer types, including rare cancers and vulnerable populations.

Conclusions:

  • 3CTN-supported ACCTs demonstrate high completion and reporting rates.
  • These trials significantly influence clinical practice and cancer care improvements.
  • Sustained infrastructure and public funding are effective for advancing evidence-based cancer policy and care.
Keywords:
Canadian Cancer Clinical Trials Network (3CTN)academic cancer clinical trialscancer guidelinescancer research impactclinical practice guidelinesevidence-based oncologyphase III trialsrare cancerstrial outcomestrial reporting

More Related Videos

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis06:27

Use of a Monocyte Monolayer Assay to Evaluate Fcγ Receptor-mediated Phagocytosis

Published on: January 2, 2017

18.7K
Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...